Therapeutics for Moderate and Severe Dengue (NCT07543458)
A Randomised Platform Trial to Evaluate Therapeutics in Patients With Moderate or Severe Dengue (DEN-HOST)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this multi-site, factorial randomised, platform trial is to evaluate host-directed therapeutic agents in patients hospitalised with moderate and severe dengue virus infection. Our primary aim is to find safe and affordable therapeutics which prevent disease progression among those at high risk for severe dengue, and improve outcomes for those with established severe disease, thereby also reducing the substantial burden placed on health systems in dengue endemic regions.
Who can join: Review the eligibility criteria below.
Location: Chittagong Medical College Hospital — Chittagong
Age range: 5 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (18 Sites)
- Chittagong Medical College Hospital — Chittagong,
- Dhaka Medical College & Hospital — Dhaka,
- Dhaka North City Corporation Hospital — Dhaka,
- Instituto de Infectologia Emílio Ribas — São Paulo,
- Centro de Atención y Diagnóstico de Enfermedades Infecciosas — Bucaramanga,
- Fundación Valle del Lili — Cali,
- Hospital Universitario Erasmo Meoz — Cúcuta,
- Universitas Sumatera Utara — Medan,
- Hospital Queen Elizabeth II, Sabah — Kota Kinabalu,
- University Malaya Medical Centre — Kuala Lumpur,
- National Academy of Medical Sciences/Bir Hospital — Kathmandu,
- Sukraraj Tropical and Infectious Disease Hospital — Kathmandu,
- Hospital Regional de Loreto — Iquitos,
- San Lazaro Hospital — Manila,
- Siriraj Hospital, Mahidol University — Bangkok,
- Prince of Songkla University in Southern Thailand — Songkhla,
- Hospital for Tropical Diseases — Ho Chi Minh City,
- Number 2 Children's Hospital — Ho Chi Minh City,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Dengue
- Improving Disease Prevention Strategies by Integrating Socio-spatial Characterization of Human Mobility — Havana, La Habana
- Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative) — Baltimore, Maryland
- Dengue Vaccine Strategy in Children Aged 9 to 17 Years in the French Caribbean — Fort-de-France,
- A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever — Manaus, Amazonas
- Risk Factors for Hospitalization and Transfusion Criteria in Patients With Dengue Virus Infection — Piedras Negras, Coahuila
Explore by condition: All Dengue clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.